Relationship of Ketosis With Myocardial Glucose Uptake Among Patients Undergoing FDG PET/CT for Evaluation of Cardiac Sarcoidosis

被引:1
|
作者
Vidula, Mahesh K. [1 ]
Selvaraj, Senthil [1 ,5 ,6 ]
Rojulpote, Chaitanya [2 ]
Bhattaru, Abhijit [2 ]
Kc, Wumesh [1 ]
Hansbury, Mary [2 ]
Schubert, Erin [2 ]
Clancy, Caitlin B. [3 ]
Rossman, Milton [3 ]
Goldberg, Lee R. [1 ]
Farwell, Michael [2 ]
Pryma, Daniel [2 ]
Bravo, Paco E. [1 ,2 ,4 ]
机构
[1] Univ Penn, Dept Med, Div Cardiovasc Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA USA
[3] Univ Penn, Dept Med, Div Pulm Med, Philadelphia, PA USA
[4] Univ Penn, Dept Radiol, Div Cardiothorac Imaging, Philadelphia, PA USA
[5] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC USA
[6] Duke Mol Physiol Inst, Durham, NC USA
关键词
blood glucose; fasting; inflammation; outpatient; sarcoidosis;
D O I
10.1161/CIRCIMAGING.124.016774
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Fluorine-18 fluorodeoxyglucose (FDG) with positron emission tomography (PET) is the standard for detecting myocardial inflammation in cardiac sarcoidosis, requiring preparation with the ketogenic diet (KD) to achieve myocardial glucose suppression. Despite this, incomplete myocardial glucose suppression remains a significant issue, and strategies to reduce myocardial glucose uptake (MGU) and identify incomplete myocardial glucose suppression are required. This study sought to understand the relationship between point-of-care beta-hydroxybutyrate (BHB) and different patterns of MGU and between KD and fasting duration with MGU in patients undergoing evaluation for cardiac sarcoidosis. METHODS: We prospectively included 471 outpatients who underwent FDG-PET for cardiac sarcoidosis evaluation, followed the KD for 1 (n=100), 2 (n=29), and >= 3 days (n=342), fasted for at least 12 hours, and had BHB levels measured immediately before FDG injection. Images were classified as (1) no MGU (negative), (2) focal/multifocal (positive), (3) diffuse (nondiagnostic), or (4) nonspecific uptake (NS-MGU). RESULTS: Cardiac FDG-PET scans were interpreted as the following: 376 (79.83%) negative; 61 (12.95%) positive; 14 (2.97%) diffuse; and 20 (4.25%) NS-MGU. There was a strong negative relationship between BHB levels and MGU (P<0.0001). BHB levels increased significantly with KD duration (P<0.0001) and fasting time (P=0.0067). The combined rate of diffuse, NS-MGU, and positive scans (34%, 28%, 16%) decreased inversely with KD duration (1, 2, and >= 3 days, respectively). However, MGU was not different across different fasting times (P=0.6). Blood glucose levels were not associated with MGU (P=0.17) and only weakly associated with BHB levels (R-2=0.03; P<0.001). CONCLUSIONS: We observed a strong inverse relationship between ketosis and patterns of MGU. Longer KD and fasting durations are associated with higher ketosis. However, only KD duration was associated with lower rates of MGU. Measurement of BHB levels before FDG-PET using point-of-care testing is feasible and may facilitate the management of patients referred for myocardial inflammation.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Comparison of the Effect of Three Different Dietary Modifications on Myocardial Suppression in 18F-FDG PET/CT Evaluation of Patients for Suspected Cardiac Sarcoidosis
    Ozutemiz, Can
    Koksel, Yasemin
    Froelich, Jerry W.
    Rubin, Nathan
    Bhargava, Maneesh
    Roukoz, Henri
    Cogswell, Rebecca
    Markowitz, Jeremy
    Perlman, David M.
    Steinberger, Daniel
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (12) : 1759 - 1767
  • [32] Metabolomic Signatures of Myocardial Glucose Uptake on FDG-PET
    Vidula, Mahesh K.
    Kelly, Daniel P.
    Arany, Zoltan
    Margulies, Kenneth B.
    Shah, Svati H.
    Petucci, Chris
    Cappola, Tom
    Bravo, Paco E.
    Selvaraj, Senthil
    CIRCULATION, 2022, 146
  • [33] The active papillary muscle sign in 18F-FDG PET/CT cardiac sarcoidosis exams and its relationship with myocardial suppression
    Ozutemiz, Can
    Koksel, Yasemin
    Froelich, Jerry W.
    Rubin, Nathan
    Bhargava, Maneesh
    Roukoz, Henri
    Cogswell, Rebecca
    Markowitz, Jeremy
    Perlman, David M.
    Steinberger, Daniel
    ANNALS OF NUCLEAR MEDICINE, 2024, 38 (05) : 391 - 399
  • [34] The active papillary muscle sign in 18F-FDG PET/CT cardiac sarcoidosis exams and its relationship with myocardial suppression
    Can Özütemiz
    Yasemin Koksel
    Jerry W. Froelich
    Nathan Rubin
    Maneesh Bhargava
    Henri Roukoz
    Rebecca Cogswell
    Jeremy Markowitz
    David M. Perlman
    Daniel Steinberger
    Annals of Nuclear Medicine, 2024, 38 : 391 - 399
  • [35] 18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis
    Skali, Hicham
    Schulman, Allison R.
    Dorbala, Sharmila
    CURRENT CARDIOLOGY REPORTS, 2013, 15 (04)
  • [36] 18F-FDG PET/CT for the Assessment of Myocardial Sarcoidosis
    Hicham Skali
    Allison R. Schulman
    Sharmila Dorbala
    Current Cardiology Reports, 2013, 15
  • [37] The Evaluation of Cardiac Sarcoidosis with F-18-FDG PET
    Al-Faham, Zaid
    Jolepalem, Prashant
    Wong, Ching Yee Oliver
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2016, 44 (02) : 92 - 93
  • [38] Serial FDG-PET/CT Imaging in the Management of Cardiac Sarcoidosis
    Bremer, William
    Sweiss, Nadera J.
    Lu, Yang
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (02) : e50 - e52
  • [39] FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab
    Miller, Christina T.
    Sweiss, Nadera J.
    Lu, Yang
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (05) : 417 - 418
  • [40] Active cardiac sarcoidosis: Diagnosis and adjustment of therapy with FDG PET/CT
    Philippe, Laurent
    Casset-Senon, Danielle
    Lorette, Gerard
    Diot, Patrice
    Cosnay, Pierre
    PRESSE MEDICALE, 2015, 44 (06): : 690 - 692